Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Zenith DrugsNSE:ZENITHDRUG -4.48%36 PEG Ratio is 0.92 as of Jul. 17, 2026, which is 15% above its 10-year median of 0.80. GuruFocus rates NSE:ZENITHDRUG with a GF Score™ of 36/100. The stock has 8 warning signs investors should review. Among 348 Drug Manufacturers companies, Zenith Drugs ranks better than 71.55% on this metric.
* The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.
The historical rank and industry rank for Zenith Drugs's PEG Ratio or its related term are showing as below:
NSE:ZENITHDRUG'
s PEG Ratio Range Over the Past 10 Years
Min: 0.73 Med: 0.8 Max: 0.98
Current: 0.92
During the past 6 years, Zenith Drugs's highest PEG Ratio was 0.98. The lowest was 0.73. And the median was 0.80.
NSE:ZENITHDRUG's PEG Ratio is ranked better than 71.55% of 348
companies
in the Drug Manufacturers industry
Industry Median: 1.715
vs NSE:ZENITHDRUG: 0.92
Peter Lynch thinks a company with a P/E ratio equal to its growth rate is fairly valued.
Zenith Drugs (NSE:ZENITHDRUG) PEG Ratio Explanation
To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the P/E ratio divided by the growth ratio. He thinks a company with a P/E ratio equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a P/E of 20, instead of a company growing 10% a year with a P/E of 10.
Zenith Drugs PEG Ratio Related Terms
Zenith Drugs PEG Ratio Historical Data
* Premium members only.
The historical data trend for Zenith Drugs's PEG Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Zenith Drugs's PEG Ratio, along with its competitors' market caps and PEG Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Zenith Drugs PEG Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Zenith Drugs's PEG Ratio distribution charts can be found below:
* The bar in red indicates where Zenith Drugs's PEG Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Note: The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.
Zenith Drugs (NSE:ZENITHDRUG) has a PEG Ratio of 0.92 as of Jul. 17, 2026. Price-earnings to growth ratio is the ratio of price-earnings to a company's earnings growth rate. View historical data on Zenith Drugs and its competitors. This is 15% above median its historical median of 0.80. Over the past decade, Zenith Drugs' PEG Ratio has ranged from 0.73 to 0.98. According to the industry distribution chart, Zenith Drugs ranks #99 out of 348 companies in the Drug Manufacturers industry, placing it in the top 28.4%.
Is Zenith Drugs' PEG Ratio too high?
Zenith Drugs' current PEG Ratio of 0.92 is 15% above median its 10-year median of 0.80. Over the past 10 years, this metric has ranged from a low of 0.73 to a high of 0.98. The Drug Manufacturers industry median PEG Ratio is 1.72. Zenith Drugs' value of 0.92 is 46.4% below this industry median. Based on the distribution chart, Zenith Drugs ranks #99 out of 348 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Zenith Drugs has a GF Score™ of 36/100, reflecting its overall financial health beyond just this single metric.
How does Zenith Drugs' PEG Ratio compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Zenith Drugs ranks #99 out of 348 companies for PEG Ratio. This puts Zenith Drugs in the upper half of its industry. The industry median PEG Ratio is 1.72. Zenith Drugs' value of 0.92 is 46.4% below this benchmark. Historically, Zenith Drugs' own PEG Ratio has ranged from 0.73 to 0.98 over the past decade. While the company's 10-year median is 0.80 vs. the industry median of 1.72, Zenith Drugs has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PEG Ratio for a Drug Manufacturers company?
The median PEG Ratio among Drug Manufacturers companies is 1.72, based on 348 companies in the industry. Companies in the top quartile (top 25%) have a PEG Ratio significantly above this median, while those in the bottom quartile fall well below. However, PEG Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Zenith Drugs's current PEG Ratio of 0.92 is 46.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PEG Ratio mean?
A high PEG Ratio can signal that a stock is expensive relative to its fundamentals. Price-earnings to growth ratio is the ratio of price-earnings to a company's earnings growth rate. View historical data on Zenith Drugs and its competitors. For the Drug Manufacturers industry, the median PEG Ratio is 1.72 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Zenith Drugs's current PEG Ratio is 0.92, which is 15% above median its own 10-year median of 0.80. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zenith Drugs stock overvalued right now?
Zenith Drugs (NSE:ZENITHDRUG) has a current PEG Ratio of 0.92. The current PEG Ratio is 0.92, which is 15% above median its 10-year median of 0.80 and 46.4% below the Drug Manufacturers industry median of 1.72. Zenith Drugs' overall GF Score™ is 36/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PEG Ratio calculated?
PEG Ratio is calculated from a company's financial statements. For Zenith Drugs (NSE:ZENITHDRUG), the current PEG Ratio is 0.92 as of Jul. 17, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Zenith Drugs Ltd is a pharmaceutical manufacturing and trading company. It offers a wide range of formulations in various forms such as ORS Powder, Liquid Orals, Ointments, Liquid Externals, Creams, Gels, Capsules, and Tablets. It is also into Generic Medicines.
36GF Score
Get the complete analysis for NSE:ZENITHDRUG
PEG Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:ZENITHDRUG has been successfully added to your 
